Aeglea BioTherapeutics to Present at BMO Capital Markets 2018 Prescription for Success Healthcare Conference
AUSTIN, Texas, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, will participate in a fireside chat at the BMO Capital Markets 2018 Prescription for Success Healthcare Conference in New York, NY on Wednesday, December 12.
Presentation DetailsDate: Wednesday, December 12, 2018Time: 3:40 p.m. ETLocation: Mandarin Oriental New York Hotel, New York CityRoom: North Salon IIWebcast: http://ir.aegleabio.com/events/event-details/bmo-capital-markets-2018-prescription-success-healthcare-conference
To access the live and archived audio webcast of the fireside chat, visit the Presentations & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. Replays of the webcast will be available for 30 days thereafter.
About Aeglea BioTherapeutics Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. Aeglea is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit http://aegleabio.com.
Investor Contact: Joey Perrone Director, Finance & Investor RelationsAeglea BioTherapeutics firstname.lastname@example.org Media Contact: David CalusdianSharon Merrill Associates617.542.5300AGLE@investorrelations.com